The "United States Hereditary Angioedema Therapeutics Market, By Region, Competition, Forecast and & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's offering.
United States Hereditary Angioedema Therapeutics Market was valued at USD 846.80 million in 2023 and is anticipated to grow with a CAGR of 7.12% through 2029.
United States Hereditary Angioedema (HAE) Therapeutics Market is an integral aspect of the nation's healthcare landscape, dedicated to addressing a rare and potentially life-threatening genetic disorder. Hereditary Angioedema manifests as recurrent and severe swelling in various body parts, including the face, hands, feet, and gastrointestinal tract. The market is primarily fueled by the imperative to offer effective treatments for individuals grappling with this debilitating condition.
Recent years have witnessed notable growth in the U.S. HAE therapeutics Market, driven by advancements in research and the development of innovative therapies. While traditional treatments like C1 inhibitor replacement therapy and bradykinin receptor antagonists have long been fundamental to HAE management, there's been a surge in the approval and adoption of modern therapies, including subcutaneous and oral options, revolutionizing the management approach. Multiple pharmaceutical companies are actively involved in developing and bringing HAE therapeutics to market in the United States.
These advancements not only enhance the quality of life for HAE patients but also broaden treatment options for healthcare providers, reducing attack frequency and severity. The U.S. HAE therapeutics market is fiercely competitive, with established and emerging players striving to offer innovative treatment options characterized by convenience, efficacy, and safety. The market's growth is propelled by heightened awareness of HAE, enhanced diagnostic capabilities, and an expanding patient population.
Mid-West emerged as the dominant player in the United States Hereditary Angioedema Therapeutics Market in 2023, holding the largest market share. The Midwest region boasts a significant patient population, which includes individuals with Hereditary Angioedema (HAE). The region's abundance of HAE treatment centers and renowned experts has drawn patients seeking specialized care.
This clustering of patients has spurred the demand for HAE therapeutics in the Midwest. Numerous pharmaceutical companies specializing in rare diseases and HAE are either headquartered or maintain a substantial presence in the Midwest. These companies have made substantial investments in research, development, and the marketing of HAE therapeutics, thereby fueling the market's expansion.
Key Market Trends
Advanced Monoclonal Antibodies
Advanced monoclonal antibodies have emerged as a potent driver propelling the United States Hereditary Angioedema (HAE) Therapeutics Market to unprecedented heights. These groundbreaking treatments signify a significant leap forward in HAE management, providing patients with prolonged defense against attacks and fundamentally altering the treatment approach.
Monoclonal antibodies such as lanadelumab (Takhzyro) and berotralstat (Orladeyo) have been instrumental in the Market, serving as prophylactic therapies. They function by inhibiting specific pathways implicated in HAE attacks, effectively preventing or mitigating the frequency and severity of these distressing episodes. Unlike conventional treatments that often necessitate frequent intravenous administrations, these advanced monoclonal antibodies are administered subcutaneously and boast extended dosing intervals, greatly enhancing patient convenience.
The advent of long-acting monoclonal antibodies has revolutionized the landscape for individuals with HAE. It not only substantially alleviates the burden of frequent injections but also affords patients a level of protection previously unattainable. With these therapies, HAE patients can now enjoy extended periods, spanning weeks or even months, between doses, granting them newfound freedom and normalcy in their daily lives.
The impact of advanced monoclonal antibodies transcends mere convenience. They hold the potential to revolutionize the lives of HAE patients by mitigating the fear, anxiety, and disruptions stemming from unpredictable attacks. These treatments provide consistent, sustained disease management, leading to a marked enhancement in overall patient quality of life and a diminished reliance on on-demand therapies.
Early Diagnosis and Genetic Testing
Early detection and genetic testing are pivotal drivers fueling the expansion of the United States Hereditary Angioedema (HAE) Therapeutics Market. These advancements play a crucial role in identifying individuals predisposed to HAE, facilitating timely intervention, personalized treatment, and enhanced patient outcomes. Given the rarity of HAE and its genetic basis, early diagnosis holds paramount importance in managing the condition effectively. Advancements in genetic testing now enable individuals to undergo testing for specific genetic mutations associated with HAE, even before symptomatic manifestation.
This proactive approach permits the implementation of personalized treatment strategies and preventative measures. Genetic testing stands out as a highly precise diagnostic tool for HAE, furnishing healthcare practitioners with conclusive insights into a patient's genetic composition. The availability of genetic testing has substantially mitigated the uncertainty previously inherent in HAE diagnosis, sparing patients from protracted diagnostic journeys marked by misdiagnoses and ineffective therapies.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 82 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value (USD) in 2024 | $846.8 Million |
| Forecasted Market Value (USD) by 2029 | $1267.15 Million |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | United States |
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the United States Hereditary Angioedema Therapeutics Market.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Seqirus Pty Ltd. (CSL Limited)
- Attune Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Pharming Healthcare N.V.
- Sanofi AG
- Cipla Ltd.
Report Scope:
United States Hereditary Angioedema Therapeutics Market, By Treatment:
- C1-esterase inhibitor
- Bradykinin B2 receptor antagonist
- Kallikrein inhibitor
- Others
United States Hereditary Angioedema Therapeutics Market, By Route of Administration:
- Intravenous
- Subcutaneous
- Oral
United States Hereditary Angioedema Therapeutics Market, By End Use:
- Prophylaxis
- On-demand
United States Hereditary Angioedema Therapeutics Market, By Region:
- North-East
- Mid-west
- West
- South
For more information about this report visit https://www.researchandmarkets.com/r/fcnus5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240717199843/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
